Bilateral hearing loss during vincristine therapy: a case report

Area of Science:

• Oncology
• Ototoxicology
• Pharmacology

Background:

• Vincristine sulfate is a critical chemotherapeutic agent for various cancers, including peripheral T-cell lymphoma.
• It is often administered in combination with other agents like cyclophosphamide and adriamycin.
• While effective, vincristine sulfate can have dose-dependent toxicities.

Observation:

• This report details a rare adverse event in a 16-year-old female patient undergoing vincristine sulfate therapy.
• The patient presented with sudden onset of bilateral hearing loss.
• The hearing loss was temporally associated with the administration of vincristine sulfate.

Findings:

• The case study documents a very rare instance of sudden bilateral hearing loss attributed to vincristine sulfate treatment.
• This adverse event occurred despite vincristine sulfate being a standard-of-care agent.
• The specific mechanism linking vincristine sulfate to ototoxicity in this case requires further investigation.

Implications:

• This case underscores the importance of monitoring for rare ototoxic side effects during vincristine sulfate chemotherapy.
• Awareness of this potential complication is crucial for early detection and management in pediatric and adolescent oncology.
• Further research into the mechanisms of vincristine-induced hearing loss may inform preventative strategies or alternative treatment options.